Abstract
INTRODUCTION Genetic associations with Alzheimer’s disease (AD) age at onset (AAO) could reveal genetic variants with therapeutic applications. We present a large Colombian kindred with autosomal dominant AD (ADAD) as a unique opportunity to discover AAO genetic associations.
METHODS A genetic association study was conducted for ADAD dementia AAO in 340 individuals with the PSEN1 E280A mutation via TOPMed array imputation. Replication was assessed in two ADAD cohorts, one sporadic EOAD study, and four late onset AD studies.
RESULTS 13 variants had p<1×10−7 or p<1×10−5 with replication including three independent loci with candidate associations with clusterin including near CLU. Other suggestive associations were identified in or near HS3ST1, HSPG2, ACE, LRP1B, TSPAN10, and TSPAN14.
DISCUSSION Variants with suggestive associations with AAO were associated with biological processes including clusterin, heparin sulfate and amyloid processing. The detection of these effects in the presence of a strong mutation for ADAD reinforce their potentially impactful role.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by the HudsonAlpha Memory and Mobility Program, the Larry L. Hillblom Foundation, the Rainwater Foundation, and NIH grants 4R00AG068271-02 (Cochran), 1R56AG062479-01 (Kosik), and 5U54NS100717-04 (Kosik) as well as the Sustainability Program of the CODI University of Antioquia (Lopera).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by the Institutional Review Board of the School of Medicine of University of Antioquia (Colombia)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript contains additional replication cohorts.
Data Availability
All summary statistics are available as supplemental material.
http://mendel.hudsonalpha.org/Public/ncochran/Colombia/E280A-AAO-SuppTable1.tsv.gz
